newsfilter
← Latest News
GlobeNewswire·

ALX Oncology to Present at Upcoming Investor Conferences in Q1 2026

  • ALX Oncology leadership will participate in the Wells Fargo Executive Biotech Summit (Feb 24-25, 2026, Lake Tahoe, CA) & TD Cowen 46th Annual Health Care Conference (March 3, 2026, 9:10 AM EST, Boston, MA).
  • ALX Oncology leadership will also attend the UBS Biotech Summit (March 10, 2026, Miami, FL).
  • The TD Cowen presentation will be webcast with a replay archived for up to 90 days via the Investors section of www.alxoncology.com.
  • Evorpacept is ALX Oncology's lead candidate & is being evaluated in multiple trials as a potential cornerstone immuno-oncology therapy.
  • ALX2004 is a novel EGFR-targeted antibody-drug conjugate currently in a Phase 1 dose-escalation trial for EGFR-expressing solid tumors.